Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNICANCER